• Home
  •  / AVEO Pharmaceuticals

AVEO Pharmaceuticals

OverviewSuggest Edit

AVEO Pharmaceuticals is a biopharmaceutical company that provides a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company develops Tivozanib, an oral, once-daily, vascular endothelial growth factor (VEGF) tyrosine kinase inhibitor (TKI) for the treatment of adult patients with advanced renal cell carcinoma. It offers therapies for cancer using proprietary genetic model systems that enable the identification of essential targets critical to the origin, maintenance and spread of malignant tumors.
TypePublic
Founded2001
HQCambridge, MA, USMap
Websiteaveooncology.com
Employee Ratings3.7More
View Jobs

Recent NewsAll News

Latest Updates

Employees (est.) (Dec 2019)19(+12%)
Revenue (FY, 2019)$28.8 M(+433%)
Share Price (Jan 2021)$8.2
Cybersecurity ratingBMore

Key People/Management at AVEO Pharmaceuticals

Erick Lucera

Erick Lucera

Chief Financial Officer
Kenneth M. Bate

Kenneth M. Bate

Lead Director
Keith Ehrlich

Keith Ehrlich

CFO
Michael N. Needle

Michael N. Needle

Chief Medical Officer
Michael P. Bailey

Michael P. Bailey

President and CEO, Director
Emile Farhan

Emile Farhan

Senior Vice President of Technical Operations and Quality Assurance
Show more

AVEO Pharmaceuticals Office Locations

AVEO Pharmaceuticals has offices in Cambridge and Boston
Cambridge, MA, US (HQ)
One Broadway, 1 Broadway 14th Floor
Boston, MA, US
30 Winter Pl
Show all (2)

AVEO Pharmaceuticals Financials and Metrics

AVEO Pharmaceuticals Revenue

AVEO Pharmaceuticals's revenue was reported to be $28.80 m in FY, 2019
USD

Revenue (Q2, 2020)

749.0k

Net income (Q2, 2020)

(7.3m)

EBIT (Q2, 2020)

(7.4m)

Market capitalization (15-Jan-2021)

235.7m

Closing stock price (15-Jan-2021)

8.2

Cash (30-Jun-2020)

45.7m

EV

202.0m
AVEO Pharmaceuticals's current market capitalization is $235.7 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

164.8m19.3m1.3m18.1m19.0m2.5m7.6m5.4m28.8m

Revenue growth, %

1302%

General and administrative expense

29.2m36.9m28.7m18.6m14.2m8.2m9.1m10.8m11.2m

R&D expense

101.7m91.4m68.5m38.3m12.9m23.7m25.2m20.7m18.0m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

26.6m3.6m860.0k1.9m1.0m323.0k324.0k323.0k15.3m1.8m873.0k134.0k134.0k15.2m1.2m193.0k992.0k2.5m351.0k4.6m1.0m433.0k2.5m1.6m703.0k25.7m784.0k749.0k

General and administrative expense

6.4m6.6m9.0m9.2m9.3m12.4m7.3m4.4m5.6m4.8m5.1m3.3m2.9m2.2m2.5m1.7m2.1m2.3m2.3m2.1m2.6m2.8m2.7m2.5m3.0m2.9m3.7m3.7m

R&D expense

25.1m20.1m24.8m21.5m21.1m21.0m16.2m19.4m11.8m9.3m8.5m2.7m1.8m4.5m6.0m5.6m4.4m8.0m6.9m4.7m5.4m4.9m5.2m6.9m2.6m4.0m7.8m4.4m

Operating expense total

31.4m26.7m33.8m30.6m30.4m33.4m23.5m23.9m17.3m14.1m13.6m6.0m4.7m6.7m8.4m7.3m6.6m10.3m9.2m6.8m8.0m7.7m7.9m9.3m5.6m6.9m11.5m8.2m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

43.5m76.1m50.8m52.3m26.6m15.1m14.9m24.4m29.8m

Accounts Receivable

7.2m20.6m984.0k2.3m4.6m1.0m402.0k3.0m1.6m

Prepaid Expenses

6.1m9.4m3.0m1.5m1.6m

Current Assets

234.4m190.7m128.9m59.1m40.4m26.3m50.2m27.9m50.6m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Cash

81.0m45.9m73.1m85.8m114.1m85.9m33.8m50.4m46.3m43.4m60.0m34.5m26.8m34.7m18.1m25.3m12.4m33.4m30.9m16.4m16.2m18.1m20.4m23.5m40.2m57.7m23.5m45.7m

Accounts Receivable

28.8m9.7m9.5m9.2m9.3m9.2m7.9m8.9m1.3m1.2m1.7m947.0k2.3m2.3m1.7m1.3m990.0k676.0k445.0k2.4m600.0k973.0k344.0k2.6m611.0k1.1m2.8m1.2m

Prepaid Expenses

9.3m5.6m3.5m5.2m7.8m9.7m9.2m7.2m2.0m3.7m3.3m1.4m1.4m1.4m1.1m

Current Assets

302.4m275.1m237.3m230.3m206.8m210.6m173.3m146.5m105.6m85.4m71.5m44.4m33.4m43.8m30.7m42.3m34.0m35.9m42.1m41.5m43.6m20.0m21.4m26.3m41.7m59.8m37.1m74.2m
show all
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

30.6m(114.4m)(107.0m)(52.7m)(15.0m)(26.9m)(65.0m)(5.3m)9.4m

Depreciation and Amortization

1.7m2.5m3.8m6.2m9.6m30.0k

Accounts Payable

(343.0k)1.7m(6.4m)(993.0k)(1.8m)760.0k250.0k1.1m(2.0m)

Cash From Operating Activities

26.5m(105.7m)(84.4m)(54.2m)(18.2m)(31.1m)(19.2m)(25.0m)(2.9m)
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Net Income

79.6m55.8m(33.2m)(62.8m)(92.9m)(34.1m)(66.0m)(90.3m)(6.4m)(24.4m)(38.8m)(10.9m)(16.3m)(8.4m)(7.7m)(16.3m)(21.3m)(8.8m)(42.1m)(68.5m)(9.0m)(5.0m)(27.1m)555.0k(2.6m)13.8m(8.4m)(15.7m)

Depreciation and Amortization

765.0k1.2m546.0k1.1m1.8m1.9m2.8m838.0k1.7m2.8m4.5m9.5m9.6m5.0k7.0k7.0k4.0k

Accounts Payable

3.7m431.0k(1.3m)(4.6m)1.4m(3.4m)(4.5m)(1.6m)(738.0k)(2.6m)(626.0k)(1.7m)(3.0m)(1.1m)656.0k(246.0k)1.1m1.2m(245.0k)944.0k386.0k547.0k(1.4m)(1.5m)(1.3m)1.5m319.0k

Cash From Operating Activities

45.5m46.4m(30.6m)(58.3m)(82.4m)(53.5m)(75.7m)(19.8m)(35.2m)(43.2m)(15.8m)(27.2m)(18.2m)(10.3m)(14.9m)(23.6m)(5.4m)(12.4m)(15.4m)(6.5m)(15.6m)(18.4m)(8.5m)(14.5m)4.5m(11.7m)(19.2m)
show all
USDQ2, 2011

Financial Leverage

1.3 x
Show all financial metrics

AVEO Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

Learn more about our premium products
SecurityScorecard logo

AVEO Pharmaceuticals Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

30-39

out of 100

Learn more about our premium products
CSRHub logo

AVEO Pharmaceuticals Online and Social Media Presence

AVEO Pharmaceuticals's Trends

Embed Graph

AVEO Pharmaceuticals News and Updates

September 16, 2020

Thinking about buying stock in Myomo Inc, Parsley Energy, Fortress Biotech, AVEO Pharmaceuticals, or Nio Inc?

NEW YORK, Sept. 16, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for MYO, PE, FBIO, AVEO, and NIO. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
September 10, 2019

Thinking about buying stock in AVEO Pharmaceuticals, CAN-FITE Biopharma, Francesca's, AT&T, or Tilray?

NEW YORK, Sept. 10, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVEO, CANF, FRAN, T, and TLRY. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
April 10, 2019

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Aveo Pharmaceuticals, Inc. of Class Action Lawsuit and Upcoming Deadline -AVEO

NEW YORK, April 9, 2019 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Aveo Pharmaceuticals, Inc. ("Aveo" or the "Company") (NASDAQ: AVEO) and certain of its officers and directors. The class action, filed in United States District Court,...
April 03, 2019

Thinking about buying stock in Aurora Cannabis Inc., Advanced Micro Devices, Aveo Pharmaceuticals, Dave & Buster's, or Riot Blockchain Inc.?

NEW YORK, April 3, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, AMD, AVEO, PLAY, and RIOT. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
March 28, 2019

Thinking about buying stock in Aveo Pharmaceuticals, Lululemon Athletica Inc., Navios Maritime, Quantenna Communications Inc., or Reebonz Ltd.?

NEW YORK, March 28, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AVEO, LULU, NMCI, QTNA, and RBZ. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....
March 05, 2019

RM LAW Announces Class Action Lawsuit Against AVEO Pharmaceuticals, Inc.

BERWYN, Pa., March 5, 2019 /PRNewswire/ -- RM LAW, P.C. announces that a class action lawsuit has been filed on behalf of all persons or entities that purchased AVEO Pharmaceuticals, Inc. ("AVEO" or the "Company") (NASDAQ: AVEO) between August 4, 2016 and January 31, 2019, inclusive (the...
Show more

AVEO Pharmaceuticals Blogs

January 20, 2021

AVEO Oncology Announces Commitment for an Incremental $10 Million Loan in Addition to Current Tranched, $35 Million Debt Facility with Hercules Capital

– $20M Tranche Available on Approval of Tivozanib – BOSTON --(BUSINESS WIRE)--Jan. 20, 2021-- AVEO Oncology (Nasdaq: AVEO) today announced that it has received a commitment letter for an incremental $10 million loan from Hercules Capital, Inc. (NYSE: HTGC, “Hercules”) and its affiliates, to be
January 15, 2021

AVEO Oncology Announces Results from Phase 1b Portion of DEDUCTIVE Study of Tivozanib (FOTIVDA®) in Combination with IMFINZI® (durvalumab) in Previously Untreated Metastatic Hepatocellular Carcinoma

– Data Presented at the 2021 ASCO GI Cancers Symposium – BOSTON --(BUSINESS WIRE)--Jan. 15, 2021-- AVEO Oncology (Nasdaq: AVEO) today announced the presentation of results from the Phase 1b portion of the Phase 1b/2 DEDUCTIVE clinical trial of tivozanib (FOTIVDA ® ), AVEO’s vascular endothelial
January 07, 2021

AVEO Oncology Highlights Recent Progress and 2021 Outlook

– Commercial Readiness Nearing Completion in Support of Potential Tivozanib U.S. Launch – – Updated IP Strategy Offers Potential for Tivozanib Patent Term Extension to November 2028 – – Corinne D. Epperly , MD, MPH, Appointed to Board of Directors – – Phase 2 Open Label Randomized Study of
January 06, 2021

AVEO Oncology Announces Participation at Two Upcoming Investor Conferences

BOSTON --(BUSINESS WIRE)--Jan. 6, 2021-- AVEO Oncology (Nasdaq: AVEO) today   announced that Michael Bailey , president and chief executive officer of AVEO, will participate in two upcoming virtual investor conferences: H.C. Wainwright Virtual BioConnect Conference Date: Monday, January 11 –
January 05, 2021

AVEO Oncology Announces Webcast of Presentation at the 39th Annual J.P. Morgan Healthcare Conference

BOSTON, Mass. --(BUSINESS WIRE)--Jan. 5, 2021-- AVEO Oncology (Nasdaq: AVEO) today   announced that Michael Bailey , president and chief executive officer of AVEO, will present at the 39 th Annual J.P. Morgan Healthcare Conference on Wednesday, January 13, 2021 at 5:20 p.m. Eastern Time .
December 16, 2020

Field-Based Marketer – West

Position Description: Reporting to the Sr. Director of Field Based Marketing, the Director of Field-Based Marketing (Central / West) will be a key member of the Marketing Team committed to ensuring the successful launch of tivozanib for RCC (renal cell carcinoma).  The Field-Based Marketing Role wil…
Show more

 AVEO Pharmaceuticals Frequently Asked Questions

  • When was AVEO Pharmaceuticals founded?

    AVEO Pharmaceuticals was founded in 2001.

  • Who are AVEO Pharmaceuticals key executives?

    AVEO Pharmaceuticals's key executives are Erick Lucera, Kenneth M. Bate and Keith Ehrlich.

  • How many employees does AVEO Pharmaceuticals have?

    AVEO Pharmaceuticals has 19 employees.

  • What is AVEO Pharmaceuticals revenue?

    Latest AVEO Pharmaceuticals annual revenue is $28.8 m.

  • What is AVEO Pharmaceuticals revenue per employee?

    Latest AVEO Pharmaceuticals revenue per employee is $1.5 m.

  • Who are AVEO Pharmaceuticals competitors?

    Competitors of AVEO Pharmaceuticals include Mirati Therapeutics, Calithera Biosciences and GlycoMimetics.

  • Where is AVEO Pharmaceuticals headquarters?

    AVEO Pharmaceuticals headquarters is located at One Broadway, 1 Broadway 14th Floor, Cambridge.

  • Where are AVEO Pharmaceuticals offices?

    AVEO Pharmaceuticals has offices in Cambridge and Boston.

  • How many offices does AVEO Pharmaceuticals have?

    AVEO Pharmaceuticals has 2 offices.